Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 19/20 | 0.52 |
| ▸ | CTSS | P25774 | 19/20 | 0.52 |
| ▸ | CTSL | P07711 | 17/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182545 | 0.84 | CTSB (0.75) | CTSBCTSSCTSLCTSK | |
| SCHEMBL7426977 | 0.80 | CTSB (0.74) | CTSBCTSSCTSLCTSK | |
| SCHEMBL6182241 | 0.79 | CTSB (0.54) | CTSBCTSSCTSLCTSKNPC1 | |
| SCHEMBL6185248 | 0.75 | RAB9A (0.47) | NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6182748 | 0.75 | CTSL (0.49) | CTSBCTSSCTSLCTSK | |
| SCHEMBL6182603 | 0.75 | CTSL (0.49) | CTSBCTSSCTSLCTSK | |
| SCHEMBL6183362 | 0.75 | CTSL (0.64) | CTSBCTSSCTSLCTSKMAPT | |
| SCHEMBL6182694 | 0.74 | CTSB (0.50) | CTSBCTSSCTSLCTSK | |
| SCHEMBL6185252 | 0.74 | RAB9A (0.48) | CTSBCTSSCTSLCTSKNPC1 | |
| SCHEMBL2918749 | 0.74 | CTSL (0.54) | CTSBCTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161415-B1 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6476026-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSB 11/4885CTSS 10/4885CTSL 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.